I was wondering this too. In a way doesn't this save the Company money while also appear to posture to the FDA that safety matters. Now all those mono HIV and Covid RTT are SOL, but the Company already has as much data as it could possibly obtain from them as proof of concept and as adjunctive data to bundle with a still needed compketed phase 3 for approval, it was all cost no gain. And the FDA is the bad guy.

Then when the HIV mono patients raise hell with the FDA saying their CD4 levels are back up after going off lero, CYDY could just respond, hey we were just concerned about patient safety like you told us. Maybe CD4 may not come back up in some of these patients who have been on it for over 5 years since all of their HIV reservoirs have disappeared like ohm said might happen and they have been cured? I realize this is optimistic thinking, but think it is possible?